New drug combo tested for tough childhood leukemia
NCT ID NCT04996160
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tested whether adding the targeted drug palbociclib to standard chemotherapy is safe for children with acute lymphoblastic leukemia that has returned or not responded to treatment. Only 2 children took part, and the main goal was to find the highest tolerable dose and understand side effects. The study is now complete, but results are not yet widely available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Palbociclib (a targeted cancer drug) combined with chemotherapy drugs (dexamethasone, bortezomib, doxorubicin)
- What this could lead to
- If this works, it could point toward a new treatment option for children with leukemia that has come back or not responded to standard therapy.
- What could go wrong
- This was a very early, tiny study (only 2 participants) focused on safety, not effectiveness. The combination may cause significant side effects, and results may not apply to other patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA, PEDIATRIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Lucile Packard Children's Hospital Stanford
Stanford, California, 94304, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we make CAR-T cells last longer in leukemia?
- Can a targeted drug combo beat the toughest childhood leukemia?
- Engineered immune cells take aim at tough childhood leukemia
- Gene test spots hidden leukemia in kids
- Selective immune cell removal may tame transplant complications
- Engineered immune cells take aim at tough childhood cancers